Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false or misleading statements about the market performance and adoption of key products, including Librela, Simparica Trio, Apoquel, and Cytopoint. It claims that Zoetis failed to disclose weakening prescription growth, market share losses, and competition impacts, which led to investor losses when the truth emerged. Investors who bought Zoetis securities during this period may be eligible for compensation and can join the lawsuit or seek lead plaintiff status by July 27, 2026.
Bernstein Liebhard LLP announced a class action lawsuit against Zoetis Inc. for allegedly making false and misleading statements about its business and financial health between January 14, 2025, and May 6, 2026. The lawsuit claims these misrepresenta...
A class action lawsuit has been filed against Zoetis Inc. and certain officers, alleging they made false statements about the growth and market share of key products in the Companion Animal segment. The complaint claims Zoetis failed to disclose weak...
Zoetis Inc. is the subject of a class action lawsuit alleging it misled investors about weakening sales of key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The lawsuit claims Zoetis and its executives failed to d...
A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concern...
A class action lawsuit has been filed against Zoetis Inc. for allegedly misleading investors about the performance of its main animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The complaint claims Zoetis failed to di...
